文献速递头颈部肿瘤放疗姑息放疗与转移瘤

系统性硬化症合并头颈部癌症患者接受放射治疗的影响

The Impact of Radiation Therapy in Patients with Systemic Sclerosis and Head and Neck Cancer.
PubMed 文献 · Pract Radiat Oncol · 2024-05-03

该病例系列从约翰霍普金斯硬化症中心与匹兹堡大学硬化症中心研究登记中识别13例接受头颈部放疗的系统性硬化症患者,5年生存率54%,9例(69%)出现局部放射性皮肤增厚、7例(54%)颈部活动度下降,系统性硬化症全身 flare 不常见,作者认为当放疗为最佳治疗选择时可支持使用放疗。

要点

  • 13例系统性硬化症合并头颈部癌症患者接受放疗,5年生存率54%。
  • 9例(69%)出现局部放射性皮肤增厚,7例(54%)颈部活动度下降。
  • 2例因放疗并发症需长期经皮内镜下胃造瘘,无患者因放疗需呼吸支持。

核心结论

  • 部分接受头颈部放疗的系统性硬化症患者出现局部皮肤增厚和颈部活动度下降,但系统性硬化症全身 flare 不常见。
  • 作者认为该观察性研究提供证据支持当放疗为最佳治疗选择时对系统性硬化症合并头颈部癌症患者使用放疗。

研究设计与样本

  • 病例系列,从约翰霍普金斯硬化症中心与匹兹堡大学硬化症中心研究登记中识别接受放疗的系统性硬化症合并头颈部癌症患者。
  • 通过病历回顾判定是否出现预设的急性和晚期副作用或系统性硬化症活动度变化,并描述用于预防和治疗放射性纤维化的疗法。
  • 共纳入13例接受头颈部癌症放疗的系统性硬化症患者。

主要发现

  • 5年生存率为54%。
  • 9例(69%)出现局部放射性皮肤增厚,7例(54%)出现颈部活动度下降。
  • 2例因放疗并发症需长期经皮内镜下胃造瘘使用,无患者因放疗需呼吸支持。
  • 在放疗前已确诊系统性硬化症的患者中,放疗后期间无患者出现间质性肺病进展。
  • 放疗后1例患者出现放射野外皮肤疾病加重,但该患者处于系统性硬化症第一年内,此时进展性皮肤疾病为预期表现。

关键数值与推荐

  • 预防放射性纤维化的治疗策略包括己酮可可碱、氨磷汀和维生素E,静脉注射免疫球蛋白(IVIG)用于治疗放射性纤维化。

临床怎么用

  • 作者认为该观察性研究提供证据支持当放疗为最佳治疗选择时对系统性硬化症合并头颈部癌症患者使用放疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Systemic sclerosis (SSc) is considered a relative, or in some cases, absolute contraindication for radiation therapy for various cancers; however, radiation is the standard of care and the best option for tumor control for locally advanced head and neck (H&N) cancer. We present a case series to document postradiation outcomes in patients with SSc and H&N cancer. METHODS: Patients with SSc and H&N cancer treated with radiation were identified from the Johns Hopkins Scleroderma Center and the University of Pittsburgh Scleroderma Center research registries. Through chart review, we identified whether patients developed predetermined acute and late side effects or changes in SSc activity from radiation. We further describe therapies used to prevent and treat radiation-induced fibrosis. RESULTS: Thirteen patients with SSc who received radiation therapy for H&N cancer were included. Five-year survival was 54%. Nine patients (69%) developed local radiation-induced skin thickening, and 7 (54%) developed reduced neck range of motion. Two patients required long-term percutaneous endoscopic gastrostomy use due to radiation therapy complications. No patients required respiratory support related to radiation therapy. Regarding SSc disease activity among the patients with established SSc before radiation therapy, none experienced interstitial lung disease progression in the postradiation period. After radiation, one patient had worsening skin disease outside the radiation field; however, this patient was within the first year of SSc, when progressive skin disease is expected. Treatment strategies to prevent radiation fibrosis included pentoxifylline, amifostine, and vitamin E, while intravenous immunoglobulin (IVIG) was used to treat it. CONCLUSION: Although some patients with SSc who received radiation for H&N cancer developed localized skin thickening and reduced neck range of motion, systemic flares of SSc were uncommon. This observational study provides evidence to support the use of radiation therapy for H&N cancer in patients with SSc when radiation is the best treatment option.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Wallwork RS, Page BR, Wigley FM, et al. The Impact of Radiation Therapy in Patients with Systemic Sclerosis and Head and Neck Cancer. Pract Radiat Oncol. 2024. PMID: 38704024. doi:10.1016/j.prro.2024.04.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。